0001213900-26-051015
SEC filingTiziana advanced its intranasal foralumab pipeline across multiple CNS indications while managing costs through IL-6R program cessation and BMS license renegotiations.
Tiziana's research and development expenses decreased in 2025, primarily due to the cessation of focus on the IL-6R program and a reduction in expected license fee expenditure following renegotiations with BMS. This strategic reprioritization allowed the company to concentrate resources on its lead asset, intranasal foralumab, for central nervous system (CNS) indications. The company's pipeline now centers on Phase 2 trials for non-active secondary progressive multiple sclerosis (na-SPMS), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS), with top-line data expected in 2026.
Despite financial constraints, Tiziana achieved several clinical and regulatory milestones in 2025. The Phase 2 trial for intranasal foralumab in na-SPMS expanded to include sites at Yale, Johns Hopkins, Cornell, and others, with top-line data expected in H2 2026. The FDA granted Fast Track designation for intranasal foralumab in na-SPMS, facilitating expedited review. In Alzheimer's disease, the Phase 2 trial began dosing in December 2025, evaluating foralumab as monotherapy and in combination with lecanemab or donanemab. The ALS Phase 2 trial was accepted into the Healey ALS MyMatch Program, and the MSA Phase 2 trial enrolled its first patient. These programs are supported by a strong safety profile: the seventh annual DSUR reported no drug-related serious adverse events after 37.4 patient-years of cumulative exposure. The company also filed multiple new patent applications covering foralumab combinations with GLP-1 agonists, anti-CD20 therapies, and anti-amyloid therapies, extending intellectual property protection into the 2040s.
Management's outlook emphasizes the upcoming top-line data readouts in 2026 as key catalysts. The directors are taking steps to secure sufficient funding to support ongoing trials and operations. The company's strategy remains focused on intranasal foralumab for CNS indications, leveraging its differentiated mechanism of action—induction of regulatory T cells to dampen microglial activation—which has shown promise in PET imaging studies. The combination approach with GLP-1 agonists for metabolic inflammation and with anti-amyloid therapies for Alzheimer's positions Tiziana at the intersection of neuroinflammation and metabolic health. However, the going concern uncertainty and reliance on external financing remain critical risks. Investors should monitor the company's ability to raise capital, clinical trial enrollment, and data readouts in the coming year.